Abdala, the first Cuban and Latin American vaccine against covid-19, celebrates this Saturday the first anniversary of its approval by the local regulatory authority for its emergency use in the mass immunization campaign on the island.
This vaccine -created and manufactured by the Center for Genetic Engineering and Biotechnology (CIGB)- has shown an efficacy of 92.28% in clinical trials. In its last phase of testing, 48,000 volunteers aged 19 to 80 participated.
–
Related posts:
Brain tumors after exposure to CT scans in children and young adults
World's First AI-Developed Drug for Idiopathic Pulmonary Fibrosis Enters Landmark Clinical Trials in...
Health .-- New principle for cancer treatment shows promising effect
LIVE | Weight gain in one in five children due to corona crisis | Inland
